174 related articles for article (PubMed ID: 38740918)
1. Integrated single-cell and bulk RNA-Seq analysis enhances prognostic accuracy of PD-1/PD-L1 immunotherapy response in lung adenocarcinoma through necroptotic anoikis gene signatures.
Sui P; Liu X; Zhong C; Sha Z
Sci Rep; 2024 May; 14(1):10873. PubMed ID: 38740918
[TBL] [Abstract][Full Text] [Related]
2. Combination of tumor mutation burden and immune infiltrates for the prognosis of lung adenocarcinoma.
Zhao Z; He B; Cai Q; Zhang P; Peng X; Zhang Y; Xie H; Wang X
Int Immunopharmacol; 2021 Sep; 98():107807. PubMed ID: 34175739
[TBL] [Abstract][Full Text] [Related]
3. Prediction of Responsiveness to PD-L1/PD-1 Inhibitors Using miRNA Profiles Associated With PD-L1 Expression in Lung Adenocarcinoma and Squamous Cell Carcinoma.
Koh YW; Han JH; Haam S; Lee HW
Anticancer Res; 2024 May; 44(5):2081-2089. PubMed ID: 38677736
[TBL] [Abstract][Full Text] [Related]
4. Development of m6A/m5C/m1A regulated lncRNA signature for prognostic prediction, personalized immune intervention and drug selection in LUAD.
Ma C; Gu Z; Yang Y
J Cell Mol Med; 2024 Apr; 28(8):e18282. PubMed ID: 38647237
[TBL] [Abstract][Full Text] [Related]
5. Signatures of Multi-Omics Reveal Distinct Tumor Immune Microenvironment Contributing to Immunotherapy in Lung Adenocarcinoma.
Huang Z; Li B; Guo Y; Wu L; Kou F; Yang L
Front Immunol; 2021; 12():723172. PubMed ID: 34539658
[TBL] [Abstract][Full Text] [Related]
6. Analysis of immune-related signatures of lung adenocarcinoma identified two distinct subtypes: implications for immune checkpoint blockade therapy.
Wang Q; Li M; Yang M; Yang Y; Song F; Zhang W; Li X; Chen K
Aging (Albany NY); 2020 Feb; 12(4):3312-3339. PubMed ID: 32091408
[TBL] [Abstract][Full Text] [Related]
7. SLC7A11 inhibits ferroptosis and downregulates PD-L1 levels in lung adenocarcinoma.
Huang Z; Chen X; Wang Y; Yuan J; Li J; Hang W; Meng H
Front Immunol; 2024; 15():1372215. PubMed ID: 38655266
[TBL] [Abstract][Full Text] [Related]
8. Gene landscape and correlation between B-cell infiltration and programmed death ligand 1 expression in lung adenocarcinoma patients from The Cancer Genome Atlas data set.
Ho KH; Chang CJ; Huang TW; Shih CM; Liu AJ; Chen PH; Cheng KT; Chen KC
PLoS One; 2018; 13(12):e0208459. PubMed ID: 30521597
[TBL] [Abstract][Full Text] [Related]
9. Trametinib sensitizes KRAS-mutant lung adenocarcinoma tumors to PD-1/PD-L1 axis blockade via Id1 downregulation.
Puyalto A; Rodríguez-Remírez M; López I; Macaya I; Guruceaga E; Olmedo M; Vilalta-Lacarra A; Welch C; Sandiego S; Vicent S; Valencia K; Calvo A; Pio R; Raez LE; Rolfo C; Ajona D; Gil-Bazo I
Mol Cancer; 2024 Apr; 23(1):78. PubMed ID: 38643157
[TBL] [Abstract][Full Text] [Related]
10. NGEF is a potential prognostic biomarker and could serve as an indicator for immunotherapy and chemotherapy in lung adenocarcinoma.
Chen X; Zhang T; He YQ; Miao TW; Yin J; Ding Q; Yang M; Chen FY; Zeng HP; Liu J; Zhu Q
BMC Pulm Med; 2024 May; 24(1):248. PubMed ID: 38764064
[TBL] [Abstract][Full Text] [Related]
11. FAM83A drives PD-L1 expression via ERK signaling and FAM83A/PD-L1 co-expression correlates with poor prognosis in lung adenocarcinoma.
Zhou F; Wang X; Liu F; Meng Q; Yu Y
Int J Clin Oncol; 2020 Sep; 25(9):1612-1623. PubMed ID: 32430734
[TBL] [Abstract][Full Text] [Related]
12. Dysregulated ferroptosis-related genes indicate potential clinical benefits for anti-PD-1/PD-L1 immunotherapy in lung adenocarcinoma.
Zhou M; Zhang X; Li T; Chen Y
J Clin Lab Anal; 2021 Dec; 35(12):e24086. PubMed ID: 34752672
[TBL] [Abstract][Full Text] [Related]
13.
Li F; Huang Q; Luster TA; Hu H; Zhang H; Ng WL; Khodadadi-Jamayran A; Wang W; Chen T; Deng J; Ranieri M; Fang Z; Pyon V; Dowling CM; Bagdatlioglu E; Almonte C; Labbe K; Silver H; Rabin AR; Jani K; Tsirigos A; Papagiannakopoulos T; Hammerman PS; Velcheti V; Freeman GJ; Qi J; Miller G; Wong KK
Cancer Discov; 2020 Feb; 10(2):270-287. PubMed ID: 31744829
[TBL] [Abstract][Full Text] [Related]
14. Elaboration and validation of a prognostic signature associated with disulfidoptosis in lung adenocarcinoma, consolidated with integration of single-cell RNA sequencing and bulk RNA sequencing techniques.
He D; Tang H; Yang X; Liu X; Zhang Y; Shi J
Front Immunol; 2023; 14():1278496. PubMed ID: 37965333
[TBL] [Abstract][Full Text] [Related]
15. Potential Predictive Value of
Dong ZY; Zhong WZ; Zhang XC; Su J; Xie Z; Liu SY; Tu HY; Chen HJ; Sun YL; Zhou Q; Yang JJ; Yang XN; Lin JX; Yan HH; Zhai HR; Yan LX; Liao RQ; Wu SP; Wu YL
Clin Cancer Res; 2017 Jun; 23(12):3012-3024. PubMed ID: 28039262
[No Abstract] [Full Text] [Related]
16. Single-cell transcriptome analysis revealed a suppressive tumor immune microenvironment in EGFR mutant lung adenocarcinoma.
Yang L; He YT; Dong S; Wei XW; Chen ZH; Zhang B; Chen WD; Yang XR; Wang F; Shang XM; Zhong WZ; Wu YL; Zhou Q
J Immunother Cancer; 2022 Jan; 10(2):. PubMed ID: 35140113
[TBL] [Abstract][Full Text] [Related]
17. Robust Prediction of Immune Checkpoint Inhibition Therapy for Non-Small Cell Lung Cancer.
Jiang J; Jin Z; Zhang Y; Peng L; Zhang Y; Zhu Z; Wang Y; Tong D; Yang Y; Wang J; Yang Y; Xiao K
Front Immunol; 2021; 12():646874. PubMed ID: 33927719
[TBL] [Abstract][Full Text] [Related]
18.
Liu L; Wang C; Li S; Qu Y; Xue P; Ma Z; Zhang X; Bai H; Wang J
Front Immunol; 2021; 12():677169. PubMed ID: 34354701
[TBL] [Abstract][Full Text] [Related]
19. B2M gene expression shapes the immune landscape of lung adenocarcinoma and determines the response to immunotherapy.
Zhao Y; Cao Y; Chen Y; Wu L; Hang H; Jiang C; Zhou X
Immunology; 2021 Nov; 164(3):507-523. PubMed ID: 34115389
[TBL] [Abstract][Full Text] [Related]
20. Development of the prognostic value in lung adenocarcinoma based on anoikis-related genes and initial experimental validation.
Guo W; Zhao G; Liu S; Deng T; Zhang G; Zhang B
J Gene Med; 2023 Sep; 25(9):e3534. PubMed ID: 37259225
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
